Trends in incidence of neuroendocrine neoplasms in Norway: A report of 16,075 cases from 1993 through 2010

Neuroendocrinology

Volumn 104, Issue 1, 2016, Pages 1-10

  Cetinkaya, Raziye Boyar ^a   Aagnes, Bjarte ^b   Thiis Evensen, Espen ^a   Tretli, Steinar ^b   Bergestuen, Deidi S ^a   Hansen, Svein ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

Epidemiology; Incidence; Neuroendocrine carcinomas; Neuroendocrine tumors; Registries

Indexed keywords

ADRENAL TUMOR; ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER STAGING; DISEASE COURSE; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NORWAY; PANCREAS CANCER; PRIORITY JOURNAL; SEX DIFFERENCE; TREND STUDY; CLASSIFICATION; INCIDENCE; LONGITUDINAL STUDY; MIDDLE AGED; NEUROENDOCRINE TUMORS; PREVALENCE; RETROSPECTIVE STUDY;

AGED; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; NORWAY; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84946780243     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000442207     Document Type: Article

References (49)

1. Kloppel G: Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 15-31.
2. Rindi G, Bordi C, La Rosa S, Solcia E, Delle Fave G: Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report. Dig Liver Dis 2011; 43(suppl 4):S356-S360.
3. DeLellis RA: The neuroendocrine system and its tumors: an overview. Am J Clin Pathol 2001; 115(suppl):S5-S16.
4. Lloyd RV: Endocrine Pathology: Differential Diagnosis and Molecular Advances. New York, Springer, 2010.
5. Oberg K, Castellano D: Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 2011; 30(suppl 1):3-7.
6. Oberg KE: The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol) 2012; 24: 282-293.
7. Modlin IM, Shapiro MD, Kidd M: An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg 2005; 29: 92-101.
8. Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204-2210.
9. Alsina M, Marcos-Gragera R, Capdevila J, Buxo M, Ortiz RM, Barretina P, Vilardell L, Brunet J, Beltran M, Izquierdo A: Neuroendocrine tumors: a population-based study of incidence and survival in Girona province, 1994-2004. Cancer Epidemiol 2011; 35:e49-e54.
10. Luke C, Price T, Townsend A, Karapetis C, Kotasek D, Singhal N, Tracey E, Roder D: Epidemiology of neuroendocrine cancers in an Australian population. Cancer Causes Control 2010; 21: 931-938.
11. Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS: The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One 2013; 8:e62487.
12. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM: Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 2655-2664.
13. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
14. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.
15. Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S: Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015; 121: 589-597.
16. Korse CM, Taal BG, van Velthuysen ML, Visser O: Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer 2013; 49: 1975-1983.
17. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72.
18. Cancer Registry of Norway: About the cancer registry. Updated 2013. Available from the organization.
19. Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, Moller B: Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009; 45: 1218-1231.
20. Solcia E KG, Sobin LH: Histological Typing of Endocrine Tumours, ed 2. Berlin, Springer, 2000.
21. Percy C VHV, Muir C: International Classification of Diseases for Oncology, ed 2. Geneva, World Health Organization, 1990.
22. Fritz A PC, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S: International Classification of Diseases for Oncology, ed 3. Geneva, World Health Organization, 2000.
23. Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO Classification of Tumours of the Digestive System, ed 4. Lyon, IARC, 2010.
24. Falconi M, Bartsch DK, Eriksson B, Kloppel G, Lopes JM, O'Connor JM, Salazar R, Taal BG, Vullierme MP, O'Toole D: ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95: 120-134.
25. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I: The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015; 10: 1243-1260.
26. Barnes L, Eveson JW, Reichart P, Sidransky D (eds): WHO Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon, IARC Press, 2005.
27. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds): WHO Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, IARC Press 2004.
28. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr: Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 2011; 114: 336-344.
29. Cunliffe CH, Fischer I, Parag Y, Fowkes ME: State-of-the-Art pathology: new WHO classification, implications, and new developments. Neuroimaging Clin N Am 2010; 20: 259-271.
30. Strosberg JR: Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol 2013; 40: 120-133.
31. Harari A, Inabnet WB 3rd: Malignant pheochromocytoma: a review. Am J Surg 2011; 201: 700-708.
32. Thompson LR: Olfactory neuroblastoma. Head Neck Pathol 2009; 3: 252-259.
33. Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P: A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 2001; 27: 85-96.
34. van Buuren S: Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007; 16: 219-242.
35. StataCorp: Multiple-Imputation Reference Manual (mi impute mlogit): Stata 14. College Station, Stata Press, 2015.
36. Doll R, Payne P, Waterhouse J: Cancer Incidence in Five Continents: A Technical Report. Berlin, Springer, 1966.
37. Tiwari RC, Clegg LX, Zou Z: Efficient interval estimation for age-Adjusted cancer rates. Stat Methods Med Res 2006; 15: 547-569.
38. StataCorp: Stata Statistical Software. College Station, StataCorp LP, 2015.
39. Consonni D, Coviello E, Buzzoni C, Mensi C: A command to calculate age-standardized rates with efficient interval estimation. Stata J 2012; 12: 688-701.
40. Cleveland WS: Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979; 74: 829-836.
41. van der Zwan JM, Trama A, Otter R, Larranaga N, Tavilla A, Marcos-Gragera R, Dei Tos AP, Baudin E, Poston G, Links T: Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer 2013; 49: 2565-2578.
42. Scherubl H, Streller B, Stabenow R, Herbst H, Hopfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM: Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol 2013; 19: 9012-9019.
43. Stenstrom G, Svardsudd K: Pheochromocytoma in Sweden 1958-1981. An analysis of the national cancer registry data. Acta Med Scand 1986; 220: 225-232.
44. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT: Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983; 58: 802-804.
45. Youlden DR, Soyer HP, Youl PH, Fritschi L, Baade PD: Incidence and survival for merkel cell carcinoma in Queensland, Australia, 1993-2010. JAMA Dermatol 2014; 150: 864-872.
46. Reichgelt BA, Visser O: Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993-2007. Eur J Cancer 2011; 47: 579-585.
47. Statement concerning the increased use of computed tomography in the Nordic countries. Updated 2012. http://www.nrpa.no/dav/db58f19fef.pdf.
48. Almén A, Friberg E, Widmark A, Olerud H: Radiology in Norway anno 2008. Trends in Examination Frequency and Collective Effective Dose to the Population:Strålevern Rapport 2010. Oslo, Norwegian Radiation Protection Authority, 2010.
49. Mocellin S, Nitti D: Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25,531). Ann Oncol 2013; 24: 3040-3044.